- Dyadic Attends Investor Events in December
- Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
- Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
- Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
- Dyadic to Present at Industry Events in November
No comments to show.